期刊文献+

小剂量多巴胺联合米力农对顽固性心力衰竭的疗效及对心功能的影响 被引量:5

Intractable Heart Failure: Efficacy of Low Dose Dopamine Combined with Milrinone and Its Influence on Heart Function
收藏 分享 导出
摘要 目的:探讨小剂量多巴胺联合米力农对顽固性心力衰竭的疗效及对心功能的影响。方法:选取2014年7月-2016年7月我院老年病科、心血管科二区收治的顽固性心力衰竭患者160例,给予常规抗心衰治疗的80例记为对照组,在对照组基础上加用小剂量多巴胺联合米力农治疗的80例记为观察组,疗程均为7 d。比较两组患者的疗效;比较两组患者的左心室射血分数(LVEF)、左室舒张末期内径(LVEDD)、肌酸激酶(CK)、肌酸激酶同工酶(CK-MB);比较两组患者治疗前后血清NT-pro BNP水平。结果:观察组总有效率为96.25%,显著高于对照组的66.25%(P〈0.05);治疗前两组LVEF、LVEDD、CK、CK-MB比较,差异无统计学意义(P〉0.05)。观察组治疗后的LVEF较对照组升高,LVEDD、CK、CK-MB较对照组降低(P〈0.05);治疗前两组患者血清NT-pro BNP水平无显著差异(P〉0.05)。经过治疗后,两组患者血清NT-pro BNP水平显著下降(P〈0.05),治疗后观察组血清NT-pro BNP水平显著低于对照组,差异有统计学意义(P〈0.05)。结论:小剂量多巴胺联合米力农治疗顽固性心力衰竭疗效显著,有助于心功能的恢复,显著降低患者血清NT-pro BNP水平,值得临床应用。 Objective: To explore the efficacy of low dose doparnine combined with milrinone in the treatment of patients with in- tractable heart failure and its influence on heart function. Methods: A total of 160 patients with intractable heart failure,who were treated in First Affiliated Hospital of Guangxi University of Chinese Medicine from July 2014 to July 2016, were selected and divided into con- trol group(n=80) and observation group(n=80). The control group was treated with conventional anti heart failure therapy, and the obser- vation group was added low dose doparnine combined with milrinone on the basis of control group's therapy. The course of treatment was 7 d. The clinical efficacy, the left ventriculai ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), creatine kinase (CK), creatine kinase isoenzym (CK-MB), and the serum NT-proBNP levels before and after treatment were compared between the two groups.Results: The total effective rate (96.25%) of the observation group was higher than that (66.25%) of the control group (P〈0.05). There were no significant differences in the levels of LVEF, LVEDD, CK, and CK-MB between the two groups before treatment(P〉0. 05).After the treatment,the level of LVEF in the observation group was higher than that in the control group, while the levels of LVEDD, CK, CK-MB were lower than those in the control group (P〈0.05). There was no significant difference in the levels of serum NT-proBNP between the two groups before treatment (P〉0.05). The levels of serum NT-proBNP were significantly decreased in the two groups after treatment (P〈0.05), and the level of serum NT-proBNP in the observation group was lower than that in the control group, the difference was statistically significant (P〈0.05). Conclusion: A small dose ofdopamine combined with milrinone is effective in the treatment of in- tractable heart failure. It is helpful to the recovery of cardiac function and can significantly
作者 林琳 唐农 刘布谷 张以昆 莫霄云 何贵新 LIN Lin1, TANG Nong2, LIU Bu-gu3, ZHANG Yi-kun1, MO Xiao-yun1, HE Gui-xin1 (1 Department of Getia~'cs, Second Ward of Cardiovascular Department, The First Aftiliated Hospital of Guangxi University of Chinese Medicine, Nanning, Guangxi, 530023, China; 2 Guangxi Universi(y Of Chinese Medicine, Nanning, Guangxi, 530200, China; 3 Outpatient Department of Internal Medicine of Traditional Chinese Medicine, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, Guangxi, 530023, China)
出处 《现代生物医学进展》 CAS 2017年第33期6498-6501,6522共5页 Progress in Modern Biomedicine
关键词 多巴胺 米力农 顽固性心力衰竭 心功能 Dopamine Milrinone Intractable heart failure Heart function
作者简介 林琳(1982-),女,硕士,主治医师,从事中西医结合老年病防治方面的研究,E-mail:kfaegb@163.com;通讯作者:何贵新(1973-),男,博士,主任医师,从事中西医结合防治心血管疾病方面的研究,E-mail:uyrfcv@163.com
  • 相关文献

参考文献7

二级参考文献79

  • 1武蓓,陈红.ACC/AHA关于顽固性心力衰竭的治疗建议[J].中国医药导刊,2005,7(2):146-146. 被引量:5
  • 2陆再英,钟南山.内科学[M].第7版.北京:人民卫生出版社.2008:251. 被引量:1994
  • 3Jebeli M,Ghazinoor M,Mandegar M H,et al.Effect of milrinonc on short-term outcome of patients with myocardial dysfunction undergoing coronary artery bypass graft:a randomized controlled trial[J].Cardiol J,2010,17(1):73-78. 被引量:1
  • 4Donlan S M,Quattromani E,Pang PS,et al.Therapy for acute heart failure syndromes[J].Curt Cardiol Pep,2009,2(3):192-201. 被引量:1
  • 5无.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095. 被引量:2807
  • 6Imamura T, Kinugawa K, Ohtani T, et al. Assessment of quality of life during long-term treatment of tolvaptan in refractory heart failure: design and rationale of the AQUA-TLV study[J]. Int Heart J, 2014, 55 (3): 264-267. 被引量:1
  • 7Nakayama M. Nonuremic indication for peritoneal dialysis for refractory heart failure in eardiorenal syndrome type U: review and perspective[J]. Petit Dial Int, 2013, 33(1): 8-14. 被引量:1
  • 8Verbrugge FH, Dupont M, Steels P, et al. The kidney in congestive heart failure: 'are nattiuresis, sodium, and diuretics really the good, the bad and the ugly?[J]. Eur J Heart Fail, 2014, 16(2): 133-142. 被引量:1
  • 9Groβekettler L, Sehmaek B, Sehwenger V. Cardiorenal syndrome: limits of heart failure therapy[J]. Herz, 2013, 38(6): 569-577. 被引量:1
  • 10Yokokawa T, Nakazato K, Kanno Y, et al. Pulmonary hypertension and refractory heart failure in a patient with Crow-Fukase (POEMS) syndrome[J]. Intern Med, 2013, 52(10): 1061-1065. 被引量:1

共引文献63

同被引文献40

二级引证文献3

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈